Chemcrux Enterprises Limited was incorporated in April 1996 to undertake the business of manufacturing or processing of Bulk Drug Intermediates like Para Chloro Benzoic, Ortho Benzoic Acid, and Lasamide etc. The Company started its business activities in the year 2000-01 by taking over the running business of M/s. Chemcrux, a partnership firm of the promoters, as a going concern. The Company made its Initial Public Offering (IPO) in March, 2017 and met with overwhelming response wherein the public offering was oversubscribed by more than 55 times, a testament to the growth story and future outlook of the Company & was listed on the Bombay Stock Exchange on 28 March, 2017. For the year 2018-19, around 100% of the total sales of the Company came from Intermediates for bulk Drugs (API), Dyes & pigment industries segment. The Company also had best capacity utilization in Chlorosulfonation & Oxidation facilities - manufacturing intermediates for bulk Drugs (API), Dyes & pigment industries. During the year 2019, the Company already achieved ISO Certification ISO 9001:2018 for Quality Management System Standard, ISO 14001: 2018 for Environmental Management System Standard. The Company has been conferred with the prestigious SKOCH Order of Merit Award for being among top 200 MSMEs of India. The award was conferred at the 57th SKOCH Summit held on 23rd March, 2019 at Constitution Club of India, New Delhi. During the year 2021, the Company received Authorized Economic Operator (AEO)-T1 Certificate from Indian Customs Board, Ministry of Finance. The Company has been accorded Certificate of Recognition as 'One Star Export House' by the Directorate General of Foreign Trade, Ministry of Commerce & Industry. The Company has featured at 1st Rank in the list of Top 50 SME Companies of India in an article published in Dalal Street Investment Journal (June 07-20, 2021 edition) based on the past financial performance and other crucial parameters. The Company has grown progressively on year-to-year basis through addition of new products as well as continuous upgradation and expansion of its manufacturing facilities. The Company has a healthy turnover and profit track record and has a robust outlook for the future.